The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells

Shuichiro Takashima, Masanori Kadowaki, Kazutoshi Aoyama, Motoko Koyama, Takeshi Oshima, Kazuma Tomizuka, Koichi Akashi, Takanori Teshima

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow transplantation (BMT), and damage to the gastrointestinal (GI) tract plays a critical role in amplifying systemic disease. Intestinal stem cells (ISCs) play a pivotal role not only in physiological tissue renewal but also in regeneration of the intestinal epithelium after injury. In this study, we have discovered that pretransplant conditioning regimen damaged ISCs; however, the ISCs rapidly recovered and restored the normal architecture of the intestine. ISCs are targets of GVHD, and this process of ISC recovery was markedly inhibited with the development of GVHD. Injection of Wnt agonist R-spondin1 (R-Spo1) protected against ISC damage, enhanced restoration of injured intestinal epithelium, and inhibited subsequent inflammatory cytokine cascades. R-Spo1 ameliorated systemic GVHD after allogeneic BMT by a mechanism dependent on repair of conditioning-induced GI tract injury. Our results demonstrate for the first time that ISC damage plays a central role in amplifying systemic GVHD; therefore, we propose ISC protection by R-Spo1 as a novel strategy to improve the outcome of allogeneic BMT.

Original languageEnglish
Pages (from-to)285-294
Number of pages10
JournalJournal of Experimental Medicine
Volume208
Issue number2
DOIs
Publication statusPublished - Feb 14 2011

Fingerprint

Graft vs Host Disease
Stem Cells
Homologous Transplantation
Bone Marrow Transplantation
Intestinal Mucosa
Gastrointestinal Tract
Cytoprotection
Wounds and Injuries
Intestines
Regeneration
Cytokines
Injections

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Takashima, S., Kadowaki, M., Aoyama, K., Koyama, M., Oshima, T., Tomizuka, K., ... Teshima, T. (2011). The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells. Journal of Experimental Medicine, 208(2), 285-294. https://doi.org/10.1084/jem.20101559

The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells. / Takashima, Shuichiro; Kadowaki, Masanori; Aoyama, Kazutoshi; Koyama, Motoko; Oshima, Takeshi; Tomizuka, Kazuma; Akashi, Koichi; Teshima, Takanori.

In: Journal of Experimental Medicine, Vol. 208, No. 2, 14.02.2011, p. 285-294.

Research output: Contribution to journalArticle

Takashima, S, Kadowaki, M, Aoyama, K, Koyama, M, Oshima, T, Tomizuka, K, Akashi, K & Teshima, T 2011, 'The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells', Journal of Experimental Medicine, vol. 208, no. 2, pp. 285-294. https://doi.org/10.1084/jem.20101559
Takashima, Shuichiro ; Kadowaki, Masanori ; Aoyama, Kazutoshi ; Koyama, Motoko ; Oshima, Takeshi ; Tomizuka, Kazuma ; Akashi, Koichi ; Teshima, Takanori. / The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells. In: Journal of Experimental Medicine. 2011 ; Vol. 208, No. 2. pp. 285-294.
@article{8b8e35d19a9a4ea8a35df79672aeab72,
title = "The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells",
abstract = "Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow transplantation (BMT), and damage to the gastrointestinal (GI) tract plays a critical role in amplifying systemic disease. Intestinal stem cells (ISCs) play a pivotal role not only in physiological tissue renewal but also in regeneration of the intestinal epithelium after injury. In this study, we have discovered that pretransplant conditioning regimen damaged ISCs; however, the ISCs rapidly recovered and restored the normal architecture of the intestine. ISCs are targets of GVHD, and this process of ISC recovery was markedly inhibited with the development of GVHD. Injection of Wnt agonist R-spondin1 (R-Spo1) protected against ISC damage, enhanced restoration of injured intestinal epithelium, and inhibited subsequent inflammatory cytokine cascades. R-Spo1 ameliorated systemic GVHD after allogeneic BMT by a mechanism dependent on repair of conditioning-induced GI tract injury. Our results demonstrate for the first time that ISC damage plays a central role in amplifying systemic GVHD; therefore, we propose ISC protection by R-Spo1 as a novel strategy to improve the outcome of allogeneic BMT.",
author = "Shuichiro Takashima and Masanori Kadowaki and Kazutoshi Aoyama and Motoko Koyama and Takeshi Oshima and Kazuma Tomizuka and Koichi Akashi and Takanori Teshima",
year = "2011",
month = "2",
day = "14",
doi = "10.1084/jem.20101559",
language = "English",
volume = "208",
pages = "285--294",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "2",

}

TY - JOUR

T1 - The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells

AU - Takashima, Shuichiro

AU - Kadowaki, Masanori

AU - Aoyama, Kazutoshi

AU - Koyama, Motoko

AU - Oshima, Takeshi

AU - Tomizuka, Kazuma

AU - Akashi, Koichi

AU - Teshima, Takanori

PY - 2011/2/14

Y1 - 2011/2/14

N2 - Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow transplantation (BMT), and damage to the gastrointestinal (GI) tract plays a critical role in amplifying systemic disease. Intestinal stem cells (ISCs) play a pivotal role not only in physiological tissue renewal but also in regeneration of the intestinal epithelium after injury. In this study, we have discovered that pretransplant conditioning regimen damaged ISCs; however, the ISCs rapidly recovered and restored the normal architecture of the intestine. ISCs are targets of GVHD, and this process of ISC recovery was markedly inhibited with the development of GVHD. Injection of Wnt agonist R-spondin1 (R-Spo1) protected against ISC damage, enhanced restoration of injured intestinal epithelium, and inhibited subsequent inflammatory cytokine cascades. R-Spo1 ameliorated systemic GVHD after allogeneic BMT by a mechanism dependent on repair of conditioning-induced GI tract injury. Our results demonstrate for the first time that ISC damage plays a central role in amplifying systemic GVHD; therefore, we propose ISC protection by R-Spo1 as a novel strategy to improve the outcome of allogeneic BMT.

AB - Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow transplantation (BMT), and damage to the gastrointestinal (GI) tract plays a critical role in amplifying systemic disease. Intestinal stem cells (ISCs) play a pivotal role not only in physiological tissue renewal but also in regeneration of the intestinal epithelium after injury. In this study, we have discovered that pretransplant conditioning regimen damaged ISCs; however, the ISCs rapidly recovered and restored the normal architecture of the intestine. ISCs are targets of GVHD, and this process of ISC recovery was markedly inhibited with the development of GVHD. Injection of Wnt agonist R-spondin1 (R-Spo1) protected against ISC damage, enhanced restoration of injured intestinal epithelium, and inhibited subsequent inflammatory cytokine cascades. R-Spo1 ameliorated systemic GVHD after allogeneic BMT by a mechanism dependent on repair of conditioning-induced GI tract injury. Our results demonstrate for the first time that ISC damage plays a central role in amplifying systemic GVHD; therefore, we propose ISC protection by R-Spo1 as a novel strategy to improve the outcome of allogeneic BMT.

UR - http://www.scopus.com/inward/record.url?scp=79951698988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951698988&partnerID=8YFLogxK

U2 - 10.1084/jem.20101559

DO - 10.1084/jem.20101559

M3 - Article

C2 - 21282378

AN - SCOPUS:79951698988

VL - 208

SP - 285

EP - 294

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 2

ER -